Fifth Third Bancorp Biomarin Pharmaceutical Inc Transaction History

Fifth Third Bancorp

$27.1 Billion
Q4 2024

A detailed history of Fifth Third Bancorp transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Fifth Third Bancorp holds 1,351 shares of BMRN stock, worth $95,231. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,351

Previous 1,186 13.91%

Holding current value

$95,231

Previous $83,000 6.02%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 21, 2025	BUY	$61.93 - $70.49 $10,218 - $11,630	165 Added 13.91%	1,351 $88,000
Q3 2024 Oct 17, 2024	SELL	$69.02 - $93.84 $24,157 - $32,844	-350 Reduced 22.79%	1,186 $83,000
Q2 2024 Jul 22, 2024	BUY	$74.43 - $92.22 $100,629 - $124,681	1,352 Added 734.78%	1,536 $126,000
Q1 2024 Apr 23, 2024	SELL	$83.81 - $99.0 $3,436 - $4,059	-41 Reduced 18.22%	184 $16,000
Q4 2023 Jan 19, 2024	SELL	$76.22 - $98.51 $134,070 - $173,279	-1,759 Reduced 88.66%	225 $21,000
Q3 2023 Oct 31, 2023	BUY	$85.07 - $94.48 $143,853 - $159,765	1,691 Added 577.13%	1,984 $175,000
Q2 2023 Jul 25, 2023	BUY	$86.68 - $100.3 $4,507 - $5,215	52 Added 21.58%	293 $25,000
Q1 2023 Apr 24, 2023	BUY	$87.74 - $117.27 $5,615 - $7,505	64 Added 36.16%	241 $23,000
Q4 2022 Jan 25, 2023	BUY	$80.93 - $108.63 $12,786 - $17,163	158 Added 831.58%	177 $0
Q3 2022 Oct 25, 2022	SELL	$82.16 - $96.94 $19,554 - $23,071	-238 Reduced 92.61%	19 $2,000
Q2 2022 Aug 04, 2022	BUY	$71.48 - $86.85 $17,012 - $20,670	238 Added 1252.63%	257 $21,000
Q1 2022 Apr 19, 2022	SELL	$74.28 - $92.69 $371 - $463	-5 Reduced 20.83%	19 $1,000
Q4 2021 Feb 01, 2022	SELL	$71.72 - $91.47 $3,083 - $3,933	-43 Reduced 64.18%	24 $2,000
Q3 2021 Oct 15, 2021	BUY	$74.77 - $85.47 $523 - $598	7 Added 11.67%	67 $5,000
Q2 2021 Aug 06, 2021	SELL	$75.51 - $84.79 $75 - $84	-1 Reduced 1.64%	60 $5,000
Q1 2021 May 07, 2021	SELL	$74.73 - $90.69 $7,024 - $8,524	-94 Reduced 60.65%	61 $5,000
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $17,063 - $21,197	-235 Reduced 60.26%	155 $14,000
Q3 2020 Nov 09, 2020	BUY	$71.87 - $131.03 $25,657 - $46,777	357 Added 1081.82%	390 $30,000
Q2 2020 Aug 05, 2020	SELL	$79.55 - $124.22 $3,500 - $5,465	-44 Reduced 57.14%	33 $4,000
Q1 2020 May 05, 2020	BUY	$71.37 - $96.85 $4,424 - $6,004	62 Added 413.33%	77 $7,000
Q4 2019 Feb 14, 2020	SELL	$64.27 - $86.37 $514 - $690	-8 Reduced 34.78%	15 $1,000
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $539 - $680	8 Added 53.33%	23 $2,000
Q1 2019 May 14, 2019	SELL	$84.2 - $98.62 $26,607 - $31,163	-316 Reduced 95.47%	15 $1,000
Q4 2018 Feb 14, 2019	BUY	$80.14 - $106.07 $5,770 - $7,637	72 Added 27.8%	331 $28,000
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $5,635 - $6,343	60 Added 30.15%	259 $25,000
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $5,902 - $7,039	-76 Reduced 27.64%	199 $16,000
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $7,510 - $8,847	93 Added 51.1%	275 $25,000
Q3 2017 Nov 14, 2017	SELL	$80.6 - $94.95 $2,014 - $2,373	-25 Reduced 12.08%	182 $17,000
Q2 2017 Aug 11, 2017	BUY	N/A	207	207 $19,000

Others Institutions Holding BMRN

# of Institutions

626

Shares Held

183M

Call Options Held

Put Options Held

1.67M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

News

Stay updated on Fifth Third Bancorp with notifications on news.

Account

Fifth Third Bancorp Biomarin Pharmaceutical Inc Transaction History